Over the last couple of decades, the role of pets in our lives have changed.

They have now become full members of the family. Illustrative of this, we spend $700 million every year on Valentine’s Day gifts for our beloved pets. We spend $1.5 billion per year for knee surgeries for our dogs.

Today, there is a critical need for, and willingness to pay for, innovative medicines for our pets. However, there are very few companies dedicated to developing such therapies. It is a burgeoning market in dire need.

KindredBio’s mission is to bring to our animal family members the same kind of innovative, breakthrough medicines that our human family members enjoy.

Our core strategy is to leverage the billions of dollars that have been invested by other companies in human pharmaceuticals by modifying, improving, and repurposing pre-existing drugs and targets that have already proven to be safe and effective in humans. For example, we are developing a canine version of Humira®, one of the most successful human biologics on the market.

By doing so, we believe that instead of the typical 5% to 10% success rate seen with new and unvalidated chemical entities in traditional drug development, we can achieve 50% to 70% success rate.

In addition, we develop most of our drugs and biologics for between $3 million to $5 million and in only 3 to 5 years. Given that most veterinary drugs reach peak sales between $10 million and $100 million per year, we believe that the return on investment is very attractive.

The companion animal biotech sector is where the human biotech sector was a generation ago. We believe that the pet pharmaceutical industry is poised to replicate the tremendous success seen in the human pharmaceutical industry over the last 25 years.

We are one of the pioneers in the pet biotech field, and we are fortunate to have one of the best teams and pipelines in the industry. Our goal is to continue to build on our leadership and transform veterinary medicine.